{"id":"NCT01218646","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of Quadrivalent Influenza Vaccine Among Adults","officialTitle":"Safety and Immunogenicity Trial Among Adults Administered Quadrivalent Influenza Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2011-03","completion":"2011-04","firstPosted":"2010-10-11","resultsPosted":"2013-09-12","lastUpdate":"2013-10-23"},"enrollment":739,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative","otherNames":[]},{"type":"BIOLOGICAL","name":"Investigational Trivalent Inactivated Influenza Vaccine, No Preservative","otherNames":[]},{"type":"BIOLOGICAL","name":"Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative","otherNames":["Fluzone®"]},{"type":"BIOLOGICAL","name":"Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative","otherNames":["Fluzone®"]}],"arms":[{"label":"Group 1: Investigational Quadrivalent Influenza Vaccine","type":"EXPERIMENTAL"},{"label":"Group 2: Investigational Trivalent Influenza Vaccine","type":"EXPERIMENTAL"},{"label":"Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine","type":"ACTIVE_COMPARATOR"},{"label":"Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain, and the investigational TIV containing the alternate B strain in adult subjects.\n\nPrimary Objective:\n\n* To demonstrate non-inferiority of antibody responses to QIV compared with licensed 2010-2011 TIV (containing the primary B strain) and investigational TIV (containing the alternate B strain) as assessed by geometric mean titer (GMT) ratios for each of the four virus strains separately among subjects 65 years of age and older\n\nObservational Objective:\n\n* To describe the safety profiles of TIV among subjects 18 years of age and older and QIV in subjects 65 years and older, as assessed by solicited injection site and systemic adverse events (AEs) collected for 7 days post-vaccination, unsolicited adverse events collected from 21 days post-vaccination, and adverse events of special interest and serious adverse events (SAEs) collected from Visit 1 to Visit 2.","primaryOutcome":{"measure":"Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines With Corresponding B Strain in Participants Aged 65 Years and Older.","timeFrame":"Day 21 post-vaccination","effectByArm":[{"arm":"Group 1 (Investigational Quadrivalent Influenza Vaccine)","deltaMin":73.8,"sd":null},{"arm":"Group 2 (Investigational Trivalent Influenza Vaccine)","deltaMin":null,"sd":null},{"arm":"Group 3 (Licensed Trivalent Influenza Vaccine)","deltaMin":57.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":225},"commonTop":["Injection site pain","Myalgia","Headache","Malaise","Injection site Swelling"]}}